Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Rui Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5794-7201; OpenAlex author ID A5100431113. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. HER3 mediates metabolic reprogramming in metastatic colorectal and pancreatic cancer Last author DOI 10.64898/2026.10.30.763164↗
  2. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Co-author DOI 10.1038/s41467-023-38921-8↗
  3. Feasibility of 125I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000035033↗
  4. HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.28421↗
  5. Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215718↗
  6. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.26502/jcsct.5079182↗
  7. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling. Co-author DOI 10.1016/j.redox.2019.101390↗
  8. ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. Co-author DOI 10.2139/ssrn.3439545↗
  9. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Co-author DOI 10.2174/1568009614666140226114015↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moeez Ghani Rathore · 3 shared papers, 2022–2026 · strength 0.70
  2. Omkar Desai · 1 shared paper, 2023 · strength 0.39
  3. Ali Vaziri Gohar · 2 shared papers, 2022–2023 · strength 0.27
  4. Mehrdad Zarei · 2 shared papers, 2022–2023 · strength 0.27
  5. Omid Hajihassani · 2 shared papers, 2022–2023 · strength 0.27
  6. Jonathan Robert Brody · 2 shared papers, 2022–2023 · strength 0.27
  7. Jordan Michael Winter · 2 shared papers, 2022–2023 · strength 0.27
  8. Shu Yang · 1 shared paper, 2023 · strength 0.22
  9. Shujing Huang · 1 shared paper, 2023 · strength 0.22
  10. Yang Zhou · 2 shared papers, 2019–2020 · strength 0.21
  11. Yunjiang Zhou · 2 shared papers, 2019–2020 · strength 0.21
  12. Rong Hu · 2 shared papers, 2019–2020 · strength 0.21
  13. Huiqin Liu · 1 shared paper, 2022 · strength 0.16
  14. Chao Kong · 1 shared paper, 2022 · strength 0.16
  15. Weijian Kong · 1 shared paper, 2022 · strength 0.16
  16. Feng Qian · 1 shared paper, 2022 · strength 0.16
  17. Wei Zhang · 1 shared paper, 2022 · strength 0.15
  18. Mahsa Zarei · 1 shared paper, 2023 · strength 0.13
  19. Jonathan J. Hue · 1 shared paper, 2023 · strength 0.13
  20. Li Zhang · 1 shared paper, 2023 · strength 0.13
  21. Costas Andreas Lyssiotis · 1 shared paper, 2023 · strength 0.13
  22. Tao Li · 1 shared paper, 2019 · strength 0.10
  23. Jun Xia · 1 shared paper, 2014 · strength 0.05
  24. Qiong Wu · 1 shared paper, 2014 · strength 0.05
  25. Zhiwei Peter Wang · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.